|
Nanobiotix is a late-stage clinical biotechnology company that develops physics-based nanotherapeutics for the treatment of cancer and neurological diseases. Founded in 2003, the company operates three nanotechnology platforms: Nanoradioenhancer, which enhances the destructive effect of radiotherapy on tumors without increasing doses to healthy tissues; Nanoprimer, designed to enable extra-hepatic administration of systemic therapies; and a platform for neurological diseases that modifies neuronal connections to alleviate symptoms. The company's lead candidate, JNJ-1900 (NBTXR3), is a first-in-class radioenhancer currently in clinical trials for solid tumors, including non-small cell lung cancer and head and neck cancers. Nanobiotix holds a global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, for the co-development and commercialization of NBTXR3. The company maintains a subsidiary in Cambridge, Massachusetts, and serves patients globally through its clinical development programs. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Biotechnology | Homepage nanobiotix.com |
| Sector Healthcare | IR page ir.nanobiotix.com | |
|
Tags
nanomedicine, radiotherapy, solid tumors, neurological diseases, oncology, clinical-stage, physics-based therapeutics, Nanoradioenhancer, Nanoprimer, JNJ-1900, NBTXR3, Curadigm Nanoprimer, Janssen Pharmaceutica NV
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | € 828.063M |
| Market cap (USD) | $ 909.959M |
| P/E | -15.85 |
| PEG | — |
| P/BV | -9.80 |
| P/S | 99.07 |
| P/OCF | -24.22 |
| P/FCF | -24.38 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 28.4% |
| ROI | — |
| ROIC | — |
| Profit margin | -80.8% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 21 |
| Quality score | -40.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2018 | FY 2017 | FY 2015 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29.643M | -11.609M | 30.058M | 4.776M | 2.647M | 2.512M | 116K | 252K | — | — | — |
| Net profit | -23.961M | -68.132M | -39.7M | -57.041M | -47.003M | -33.59M | — | — | — | — | — |
| Free cash flow | -33.96M | -20.397M | -12.804M | -37.196M | -30.1M | -27.634M | — | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Balance sheet detail | |||||||
| Trade receivables (EUR) | — | 62,000 | 0.00 | 101,000 | 905,000 | 2.98M | 2.14M |
| ↳ YoY growth | -100.0% | +796.0% | +229.0% | -28.2% | |||
| ↳ 5y CAGR | +103.0% | ||||||
| Cash and deposits (EUR) | 35.1M | 119M | 83.9M | 41.4M | 75.3M | 49.7M | 52.8M |
| Intangible assets (EUR) | — | 21,000 | 4,000 | 1,000 | 8,000 | 7,000 | 10,000 |
| Cash flow detail | |||||||
| Operating cash flow (EUR) | — | -27.5M | -29.9M | -37.1M | -12.5M | -19.6M | -33.4M |
| Purchases of property, plant and equipment (EUR) | — | -96,000 | -228,000 | -92,000 | -328,000 | -846,000 | -538,000 |
| Purchases of intangible assets (EUR) | — | -11,000 | -5,000 | -1,000 | -9,000 | -2,000 | -8,000 |
| Change in receivables (cash effect) (EUR) | — | -51,000 | 62,000 | -101,000 | -806,000 | -2.07M | 840,000 |
| Change in payables (cash effect) (EUR) | — | -995,000 | -281,000 | 2.91M | 8.68M | 1.96M | -5.41M |
| Interest paid (cash effect) (EUR) | — | -700,000 | -1.13M | -915,000 | -6.98M | -980,000 | -1.53M |
| Income taxes paid (cash effect) (EUR) | — | — | — | 0.00 | -7,000 | -62,000 | -198,000 |
| Share-based compensation (EUR) | — | 2.92M | 3.2M | 3.17M | 3.22M | 4.3M | 3.54M |
| Operating cash flow before change in receivables (EUR) | — | -27.5M | -29.9M | -37M | -11.7M | -17.5M | -34.3M |
| Free cash flow (OCF - PPE - intangibles) (EUR) | — | -27.6M | -30.1M | -37.2M | -12.8M | -20.4M | -34M |
| Income detail | |||||||
| Research and development expense (EUR) | — | 24.3M | 30.4M | 32.6M | 38.4M | 40.5M | 23.1M |
| ↳ 5y CAGR | -1.0% | ||||||
| Total comprehensive income (EUR) | — | -33.5M | -46.9M | -57M | -39.7M | -68.2M | -24M |
| Reported | Apr 8, 2022 | Apr 8, 2022 | Apr 8, 2022 | Apr 24, 2024 | Apr 24, 2024 | Apr 2, 2025 | Mar 31, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpRegulated information filed with the AMF (info-financiere.gouv.fr), newest first, titles as filed. Voting-rights totals, own-share transactions, threshold crossings and availability notices are left out. The link opens the filed document. Material events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Nov. 12, 2026 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Bloomberg: NANO:FP
Reuters: NANO.PA
Date
Number of Shares
Outstanding
Total number of voting rights
Total voting rights,
theoretical1 Total voting rights,
exercisable2
October 31, 2026 50,968,893 54,726,179 54,704,061
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Nanobiotix S.A.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.